In patients with prostate cancer [16], myelodysplastic syndrome [17], chronic obstructive pulmonary disease [18] and bladder cancer [19], low ALT correlates with sarcopenia or frailty and is an adverse predictor. This evidence concerns the gene GPT and prostate cancer.